{"id":78507,"date":"2026-09-03T17:02:08","date_gmt":"2026-09-03T09:02:08","guid":{"rendered":"https:\/\/flcube.com\/?p=78507"},"modified":"2026-09-03T17:02:09","modified_gmt":"2026-09-03T09:02:09","slug":"hutchmed-strikes-up-to-usd-1-295-billion-deal-with-gsk-for-hmpl-a830-its-first-in-class-kras-attc-cancer-candidate","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78507","title":{"rendered":"HutchMed Strikes Up to USD 1.295 Billion Deal with GSK for HMPL\u2011A830, Its First\u2011in\u2011Class KRAS ATTC Cancer Candidate"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>HutchMed (China) Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/HCM:NASDAQ\">NASDAQ: HCM<\/a>; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/0013:HKG\">HKG: 0013<\/a>) announced today that its subsidiary, <strong>HUTCHMED Limited<\/strong>, has entered into an exclusive development and license agreement with a subsidiary of <strong>GSK<\/strong>, granting <strong>GSK<\/strong> worldwide rights (excluding China \u2014 Mainland, Hong Kong, Macau and Taiwan) to develop and commercialize <strong>HMPL\u2011A830<\/strong>, a first\u2011in\u2011class Antibody\u2011Targeted Therapy Conjugate (ATTC). The deal delivers a USD 110 million upfront payment and up to USD 1.295 billion in total potential value including development, regulatory and commercial milestones, plus royalties on net sales \u2014 one of the largest outbound oncology licensing transactions from China this year.<\/p>\n\n\n\n<h2 id=\"h-deal-terms-at-a-glance\" class=\"wp-block-heading\">Deal Terms at a Glance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Parties<\/td><td><strong>HUTCHMED Limited<\/strong> (subsidiary of <strong>HutchMed<\/strong>) and a subsidiary of <strong>GSK<\/strong><\/td><\/tr><tr><td>Asset<\/td><td><strong>HMPL\u2011A830<\/strong>, first\u2011in\u2011class ATTC<\/td><\/tr><tr><td>Rights Granted<\/td><td><strong>GSK<\/strong>: worldwide (ex\u2011China) development and commercialization<\/td><\/tr><tr><td>Rights Retained<\/td><td><strong>HUTCHMED<\/strong>: full development and commercialization rights in China; global Phase I responsibility<\/td><\/tr><tr><td>Upfront Payment<\/td><td>USD 110 million<\/td><\/tr><tr><td>Total Potential Value<\/td><td>Up to USD 1.295 billion (incl. development, regulatory and commercial milestones)<\/td><\/tr><tr><td>Royalties<\/td><td>On net sales<\/td><\/tr><tr><td>Additional Rights<\/td><td><strong>GSK<\/strong> holds right of first negotiation on one earlier\u2011stage ATTC candidate<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>HMPL\u2011A830<\/strong>, a first\u2011in\u2011class Antibody\u2011Targeted Therapy Conjugate (ATTC) drug candidate<\/li>\n\n\n\n<li><strong>Design:<\/strong> A highly selective and potent <strong>KRAS<\/strong> small\u2011molecule inhibitor payload conjugated to an <strong>anti\u2011EGFR antibody<\/strong><\/li>\n\n\n\n<li><strong>Innovation:<\/strong> The ATTC platform enables tumor\u2011selective activity of potent, cell\u2011killing payloads by leveraging antibody\u2011guided therapy \u2014 aiming to widen the therapeutic window of KRAS inhibition<\/li>\n\n\n\n<li><strong>Target Indications (Initial):<\/strong> Colorectal, pancreatic and lung cancers \u2014 tumor types with high unmet need and frequent KRAS\/EGFR pathway involvement<\/li>\n\n\n\n<li><strong>Platform Optionality:<\/strong> The <strong>GSK<\/strong> right of first negotiation on an additional earlier\u2011stage ATTC candidate underscores the breadth of <strong>HUTCHMED&#8217;s<\/strong> conjugate pipeline<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-development-plan-global-phase-i\" class=\"wp-block-heading\">Clinical Development Plan \u2013 Global Phase I<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Trial Identifier<\/td><td>NCT07718581 (ClinicalTrials.gov)<\/td><\/tr><tr><td>Expected Start<\/td><td>Second half of 2026<\/td><\/tr><tr><td>Lead Sponsor (Phase I)<\/td><td><strong>HUTCHMED Limited<\/strong> (global program)<\/td><\/tr><tr><td>Post\u2011Phase I Responsibility<\/td><td><strong>GSK<\/strong> subsidiary for all subsequent clinical development and commercialization outside China<\/td><\/tr><tr><td>China Rights<\/td><td><strong>HUTCHMED<\/strong> retains full development and commercialization in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The division of labor preserves <strong>HUTCHMED&#8217;s<\/strong> strategic footing in its home market while shifting ex\u2011China execution risk and cost to <strong>GSK<\/strong>, whose global oncology commercial infrastructure positions <strong>HMPL\u2011A830<\/strong> for broad international development.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Deal scale:<\/strong> Up to USD 1.295 billion in total consideration, anchored by USD 110 million upfront, reinforces the momentum of China\u2011originated oncology out\u2011licensing deals<\/li>\n\n\n\n<li><strong>Hot target convergence:<\/strong> <strong>HMPL\u2011A830<\/strong> pairs two validated oncology modalities \u2014 KRAS inhibition and EGFR\u2011directed delivery \u2014 in a market where KRAS\u2011targeted therapies are among the most actively pursued assets in solid tumors<\/li>\n\n\n\n<li><strong>Pipeline validation:<\/strong> <strong>GSK&#8217;s<\/strong> right of first negotiation on a second ATTC candidate signals confidence in <strong>HUTCHMED&#8217;s<\/strong> conjugate platform beyond a single asset<\/li>\n\n\n\n<li><strong>Financial flexibility:<\/strong> The upfront payment strengthens <strong>HutchMed&#8217;s<\/strong> balance sheet to fund its broader oncology pipeline, while retained China rights preserve a potential domestic revenue stream for <strong>HMPL\u2011A830<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2014 This brief contains forward\u2011looking statements regarding the development timeline, clinical plans, milestone achievement, and commercial potential of <strong>HMPL\u2011A830<\/strong>. Actual results may differ materially due to clinical, regulatory, competitive, and market risks. No investment decision should be made solely on the basis of this brief.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced today that its subsidiary, HUTCHMED Limited, has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[35,184,1105,285,1104],"class_list":["post-78507","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-adc-xdc","tag-gsk","tag-hkg-0013","tag-hutchmed","tag-nasdaq-hcm"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HutchMed Strikes Up to USD 1.295 Billion Deal with GSK for HMPL\u2011A830, Its First\u2011in\u2011Class KRAS ATTC Cancer Candidate - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced today that its subsidiary, HUTCHMED Limited, has entered into an exclusive development and license agreement with a subsidiary of GSK, granting GSK worldwide rights (excluding China \u2014 Mainland, Hong Kong, Macau and Taiwan) to develop and commercialize HMPL\u2011A830, a first\u2011in\u2011class Antibody\u2011Targeted Therapy Conjugate (ATTC). The deal delivers a USD 110 million upfront payment and up to USD 1.295 billion in total potential value including development, regulatory and commercial milestones, plus royalties on net sales \u2014 one of the largest outbound oncology licensing transactions from China this year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=78507\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HutchMed Strikes Up to USD 1.295 Billion Deal with GSK for HMPL\u2011A830, Its First\u2011in\u2011Class KRAS ATTC Cancer Candidate\" \/>\n<meta property=\"og:description\" content=\"HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced today that its subsidiary, HUTCHMED Limited, has entered into an exclusive development and license agreement with a subsidiary of GSK, granting GSK worldwide rights (excluding China \u2014 Mainland, Hong Kong, Macau and Taiwan) to develop and commercialize HMPL\u2011A830, a first\u2011in\u2011class Antibody\u2011Targeted Therapy Conjugate (ATTC). The deal delivers a USD 110 million upfront payment and up to USD 1.295 billion in total potential value including development, regulatory and commercial milestones, plus royalties on net sales \u2014 one of the largest outbound oncology licensing transactions from China this year.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=78507\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-03T09:02:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-03T09:02:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78507#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78507\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HutchMed Strikes Up to USD 1.295 Billion Deal with GSK for HMPL\u2011A830, Its First\u2011in\u2011Class KRAS ATTC Cancer Candidate\",\"datePublished\":\"2026-09-03T09:02:08+00:00\",\"dateModified\":\"2026-09-03T09:02:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78507\"},\"wordCount\":557,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"GSK\",\"HKG: 0013\",\"HutchMed\",\"NASDAQ: HCM\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78507#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78507\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=78507\",\"name\":\"HutchMed Strikes Up to USD 1.295 Billion Deal with GSK for HMPL\u2011A830, Its First\u2011in\u2011Class KRAS ATTC Cancer Candidate - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-03T09:02:08+00:00\",\"dateModified\":\"2026-09-03T09:02:09+00:00\",\"description\":\"HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced today that its subsidiary, HUTCHMED Limited, has entered into an exclusive development and license agreement with a subsidiary of GSK, granting GSK worldwide rights (excluding China \u2014 Mainland, Hong Kong, Macau and Taiwan) to develop and commercialize HMPL\u2011A830, a first\u2011in\u2011class Antibody\u2011Targeted Therapy Conjugate (ATTC). The deal delivers a USD 110 million upfront payment and up to USD 1.295 billion in total potential value including development, regulatory and commercial milestones, plus royalties on net sales \u2014 one of the largest outbound oncology licensing transactions from China this year.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78507#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78507\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78507#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HutchMed Strikes Up to USD 1.295 Billion Deal with GSK for HMPL\u2011A830, Its First\u2011in\u2011Class KRAS ATTC Cancer Candidate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HutchMed Strikes Up to USD 1.295 Billion Deal with GSK for HMPL\u2011A830, Its First\u2011in\u2011Class KRAS ATTC Cancer Candidate - Insight, China&#039;s Pharmaceutical Industry","description":"HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced today that its subsidiary, HUTCHMED Limited, has entered into an exclusive development and license agreement with a subsidiary of GSK, granting GSK worldwide rights (excluding China \u2014 Mainland, Hong Kong, Macau and Taiwan) to develop and commercialize HMPL\u2011A830, a first\u2011in\u2011class Antibody\u2011Targeted Therapy Conjugate (ATTC). The deal delivers a USD 110 million upfront payment and up to USD 1.295 billion in total potential value including development, regulatory and commercial milestones, plus royalties on net sales \u2014 one of the largest outbound oncology licensing transactions from China this year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=78507","og_locale":"en_US","og_type":"article","og_title":"HutchMed Strikes Up to USD 1.295 Billion Deal with GSK for HMPL\u2011A830, Its First\u2011in\u2011Class KRAS ATTC Cancer Candidate","og_description":"HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced today that its subsidiary, HUTCHMED Limited, has entered into an exclusive development and license agreement with a subsidiary of GSK, granting GSK worldwide rights (excluding China \u2014 Mainland, Hong Kong, Macau and Taiwan) to develop and commercialize HMPL\u2011A830, a first\u2011in\u2011class Antibody\u2011Targeted Therapy Conjugate (ATTC). The deal delivers a USD 110 million upfront payment and up to USD 1.295 billion in total potential value including development, regulatory and commercial milestones, plus royalties on net sales \u2014 one of the largest outbound oncology licensing transactions from China this year.","og_url":"https:\/\/flcube.com\/?p=78507","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-03T09:02:08+00:00","article_modified_time":"2026-09-03T09:02:09+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=78507#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=78507"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HutchMed Strikes Up to USD 1.295 Billion Deal with GSK for HMPL\u2011A830, Its First\u2011in\u2011Class KRAS ATTC Cancer Candidate","datePublished":"2026-09-03T09:02:08+00:00","dateModified":"2026-09-03T09:02:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=78507"},"wordCount":557,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","GSK","HKG: 0013","HutchMed","NASDAQ: HCM"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=78507#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=78507","url":"https:\/\/flcube.com\/?p=78507","name":"HutchMed Strikes Up to USD 1.295 Billion Deal with GSK for HMPL\u2011A830, Its First\u2011in\u2011Class KRAS ATTC Cancer Candidate - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-03T09:02:08+00:00","dateModified":"2026-09-03T09:02:09+00:00","description":"HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced today that its subsidiary, HUTCHMED Limited, has entered into an exclusive development and license agreement with a subsidiary of GSK, granting GSK worldwide rights (excluding China \u2014 Mainland, Hong Kong, Macau and Taiwan) to develop and commercialize HMPL\u2011A830, a first\u2011in\u2011class Antibody\u2011Targeted Therapy Conjugate (ATTC). The deal delivers a USD 110 million upfront payment and up to USD 1.295 billion in total potential value including development, regulatory and commercial milestones, plus royalties on net sales \u2014 one of the largest outbound oncology licensing transactions from China this year.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=78507#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=78507"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=78507#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HutchMed Strikes Up to USD 1.295 Billion Deal with GSK for HMPL\u2011A830, Its First\u2011in\u2011Class KRAS ATTC Cancer Candidate"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78507","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=78507"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78507\/revisions"}],"predecessor-version":[{"id":78508,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78507\/revisions\/78508"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=78507"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=78507"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=78507"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}